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The autosomal-recessive form of popliteal pterygium syndrome, also known as Bartsocas-Papas syndrome, is a rare, but frequently lethal
disorder characterized by marked popliteal pterygium associated with multiple congenital malformations. Using Affymetrix 250K SNP
array genotyping and homozygosity mapping, we mapped this malformation syndrome to chromosomal region 21q22.3. Direct
sequencing of RIPK4 (receptor-interacting serine/threonine kinase protein 4) showed a homozygous transversion (c.362T>A) that causes
substitution of a conserved isoleucine with asparagine at amino acid position 121 (p.Ile121Asn) in the serine/threonine kinase domain
of the protein. Additional pathogenic mutations—a homozygous transition (c.551C>T) that leads to a missense substitution
(p.Thr184Ile) at a conserved position and a homozygous one base-pair insertion mutation (c.777_778insA) predicted to lead to a prema-
ture stop codon (p.Arg260ThrfsX14) within the kinase domain—were observed in two families. Molecular modeling of the kinase
domain showed that both the Ile121 and Thr184 positions are critical for the protein’s stability and kinase activity. Luciferase reporter
assays also demonstrated that these mutations are critical for the catalytic activity of RIPK4. RIPK4 mediates activation of the nuclear
factor-kB (NF-kB) signaling pathway and is required for keratinocyte differentiation and craniofacial and limb development. The pheno-
type of Ripk4/mice is consistent with the human phenotype presented herein. Additionally, the spectrum of malformations observed
in the presented families is similar, but less severe than the conserved helix-loop-helix ubiquitous kinase (CHUK)-deficient human fetus
phenotype; known as Cocoon syndrome; this similarity indicates that RIPK4 and CHUKmight function via closely related pathways to
promote keratinocyte differentiation and epithelial growth.Limb pterygium syndromes (LPSs) are a clinically and
genetically heterogeneous group of multiple-congenital-
anomaly disorders characterized by multiple webbing on
the neck, elbows, and knees that limit joint mobility and
a wide range of other ectodermal structural abnormali-
ties.1,2 A well-known component of the LPS spectrum is
popliteal pterygium syndrome (PPS) [MIM 119500]—an
autosomal-dominant disease characterized by cleft lip
and/or palate, lip pits, and digital and genital abnormali-
ties, in addition to popliteal pterygium.1,3,4 Heterozygous
mutations in IRF6, which encodes interferon regulatory
factor 6 [MIM 607199], cause the autosomal-dominant
form of PPS, although there is evidence for genetic hetero-
geneity.5,6 An autosomal-recessive form of PPS, described
as lethal-type popliteal pterygium syndrome (LPPS) [MIM
263650] and also known as Bartsocas-Papas syndrome, is
characterized by amore severe phenotype than that associ-
ated with the autosomal-dominant form.7 The primary
characteristics of Bartsocas-Papas syndrome are as follows:
(1) marked popliteal pterygium leading to severe arthrog-
ryposis, synostosis of the carpal/tarsal and phalangeal
bones in the hands and feet, digital hypoplasia/aplasia,
and complete soft-tissue syndactyly; (2) lack of nails; (3)
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coloboma, and microphthalmia; (5) cleft lip and/or palate,
facial cleft, filiform bands between the jaws, and hypo-
plastic nasal tip; (6) hypoplastic external genitalia; and
(7) fetal and neonatal morbidity.1–4,7 Although Bartsocas-
Papas syndrome was initially considered as a lethal
disorder, there are reported cases at 2, 8, and 18 years of
age,8,9 supporting extensive clinical variability even for
life span in LPPS. To date no gene has been associated
with the autosomal-recessive form of PPS.
We studied a consanguineous Turkish family (BPS1) (Fig-
ures 1A–D and 2B), originally reported by Aslan et al.10
Marked popliteal pterygium associated with multiple
congenital anomalies was observed in six members of the
family, four of whom died within a week after birth. At the
time this report was written, affected individuals V-12 and
VI-3 (Figure 2B) were alive and 13 and 1.5 years old, respec-
tively. Common shared findings in both were alopecia,
ankyloblepharon filiforme adnatum, hypoplastic oral
cavity and filiform bands between the jaws, limb abnor-
malities (including digital hypoplasia, syndactyly, nail
hypoplasia, arthrogryposis, clubfeet, and popliteal, axil-
lary, and inguinal pterygia), and hypoplastic labia major
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Figure 1. Clinical Characterization of the Affected Individuals
from the BPS1 and BPS2 Families
(A and B) Frontal view of individual VI-3 from family BPS1
showing alopecia, ectropion, upslanting palpebral fissures, ante-
verted nostrils, oral clefts more prominent on the left side, syne-
chia between lips, marked popliteal pterygium, total syndactyly
of toes, and synechia of feet to genital region and fused digital
mass of right hand.
(C) X-ray scan of individual VI-3 from family BPS1 presenting
synostosis of phalangeal bones of the toes and missing metatar-
sals.
(D) Pelvic ultrasonography of individual VI-3 from family BPS1
showing a bicornuate uterus. Arrows indicate the two horns of
the bicornuate uterus.
(E and F) Frontal view of individual IV-1 from family BPS2 present-
ing alopecia, scaly skin, ectropion, cloudy cornea, anteverted nos-
trils, oral clefts, synechia between lips, and syndactlylous missing
fingers of both hands, severe popliteal pterygia, syndactyly of toes,
and ambiguous genitalia (phallus and incomplete fusion of genital
folds, and scrotal folds), and an inferiorly placed umbilicus.findings,11–14 individual V-12 had additional abnormali-
ties, including medial canthal webbing, hypoplasia of the
iliac wing and scapulae, short stature, anal stenosis, and
a rectal polyp (Table 1). Therefore, the initial diagnosis of
individual V-12 was considered as variant of autosomal-
recessive multiple pterygium syndrome (Aslan type)
[MIM 605203].10 DNA samples were obtained from family
members after receiving written informed consent from
the adults and parents of children. The study protocol
was approved by the Karadeniz Technical University,
Faculty of Medicine Ethics Committee (approval number:
2010/5).
Genome-wide homozygosity mapping of the two
affected (V-12 and VI-3) and ten unaffected membersThe Am(V-1, V-2, VI-1, VI-2, IV-9, IV-10, V-5, V-6, V-8, and V-10)
of the family was performed with Affymetrix 250K SNP
arrays. A single homozygous segment on chromosomal
region 21q22 was observed.Within this region, haplotypes
residing between SNP markers rs2838045 and rs225444
were identical in both affected individuals, which indi-
cated homozygosity by descent (Figure 2A). Subsequent
microsatellite-marker genotyping that included all family
members confirmed the 21q22.3 locus (Figure 2B). Critical
recombination events observed in two healthy family
members (VI-2 and V-10) positioned the mutant gene
between SNP markers rs2838045 and rs225444, within
an interval of approximately 0.71 Mb (Figure 2B). In this
critical region there are seven protein-coding genes,
TMPRSS2 [MIM 602060], RIPK4 [MIM 605706], PRDM15,
C2CD2, ZNF295, UMODL1 [MIM 613859], and ABCG1
[MIM 603076] and three expressed sequence tags.
The human ortholog of the mouse receptor-interacting
serine/threonine-protein kinase 4 gene (RIPK4) was a
highly relevant candidate gene because homozygous
Ripk4 knockout mice (Ripk4/) exhibit such severe ecto-
derm-originated organ anomalies as short limbs and tail
partially fused to the body cavity; digital fusion; atresia
of the oral cavity, esophagus, and all external orifices;
reduced skin folds; and disrupted keratinocyte differentia-
tion leading to expanded spinous and granular layers and
an outermost layer of parakeratotic cells instead of enucle-
ated squamous cells.15,16 Homozygous Ripk4-deficient
mice are not viable and die within several hours after birth
because of suffocation caused by oral fusion. Heterozygous
Ripk4-deficient mice (Ripk4þ/) are normal.15,16
Sequencing of all 8 exons and exon-intron boundaries of
RIPK4 (NM_020639) from the genomic DNA of affected
individual V-12 showed a homozygous c.362T>A transver-
sion in the second exon of the gene, which leads to sub-
stitution of asparagine with an evolutionarily highly
conserved isoleucine at position 121 (p.Ile121Asn) in the
serine/threonine kinase domain of the protein (Figure 2C).
Primer3 web software was used to design primer sequences
for amplification and the subsequent sequencing reaction
(Table S1, available online).17 The detected c.362T>A
mutation was tested in all available family members with
the amplification refractory mutation system (ARMS)
(Table S2). Both affected individuals (VI-3 and V-12) were
homozygous, and the parents and individuals VI-1, VI-2,
VI-4, VI-8, V-5, V-6, and V-10 were heterozygous for this
mutation (Figure 2D). The c.362T>A substitution was not
detected with the ARMS protocol in 336 healthy Turkish
control samples.
We extended the study to an additional Turkish family
(BPS2) with one affected male child that exhibited the
primary characteristic features of Bartsocas-Papas syn-
drome (his parents are first cousins) (Figures 1E–1F and
3A and Table 1). Unfortunately, we could not obtain
a DNA sample from the affected individual because he
died prior to the study; however, DNA sequencing analysis
of RIPK4 in parental DNA showed that both parents wereerican Journal of Human Genetics 90, 76–85, January 13, 2012 77
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Figure 2. Homozygosity Mapping and Mutation Analysis in Family BPS1
(A) Schematic representation of the genome-wide homozygosity mapping data. Genotype files (CHP files) were generated with Affyme-
trix GTYPE software and were transferred to the VIGENOS (Visual Genome Studio) program (Hemosoft, Ankara), which facilitates
visualization of a large quantity of genomic data in comprehensible visual screens. Homozygous genotypes identical to the genotype
data obtained from the affected individual V-12 are shown in blue, whereas contrasting homozygote genotypes are shown in white
and heterozygous SNPs appear in orange. Noninformative SNPs appear in yellow, and gray indicates no call. A single homozygote
segment approximately 0.71Mb in size was observed and is marked in the rectangle. Microsatellite DNA markers selected from the
interval are shown on the right side of the image.
(B) Pedigree and haplotype analysis of family BPS1 linked to chromosomal region 21q22.3. Genotyping data and haplotype bars for 21q
markers are shown below the symbol for each individual. The order of DNA markers was obtained from the UCSC Human Genome
Working Draft (build 36.1) and is listed on the left side of each genotype. Black bars denote the disease-associated region. Thin bars repre-
sent noninformative genotypes. SNP markers harboring the critical region are marked as bold.
(C) Sequence chromatograms showing the identified c.362T>A mutation in RIPK4 in family BPS1. The upper chromatogram shows the
homozygous mutant sequence, and the lower chromatogram shows the wild-type sequences.
(D) Genotypes of the c.362T>A mutation in 21 members of family BPS1 were analyzed with the amplification refractory mutation
system. The upper panel shows the wild-type allele (wt) and the lower panel shows the mutant allele (mt). Asterisks (*) indicate the
affected family members.heterozygous for a c.551C>T transition in the third exon,
which leads to substitution of isoleucine with threonine at
evolutionarily conserved position 184 (p.Thr184Ile) in the
serine/threonine kinase domain of the protein (Figures 3B
and 4A–4C). This change was not detected with the ARMS
protocol with allele-specific primers (Table S2) in 336
healthy controls.
Recently, a consanguineous Egyptian family (BPS3)
with one affected and two healthy siblings was referred
to us (Figure 3C and Table 1).18 The 3.5-month-old affected
individual had total absence of body hair and multiple
pterygia in almost all joints of the body, including shoul-
ders, elbows, wrists, hips, knees, and ankles. A very large78 The American Journal of Human Genetics 90, 76–85, January 13, 2and thick popliteal pterygium and severe distortion of
both lower limbs was observed. There were multiple eye
anomalies and a bilateral orofacial cleft that did not follow
the embryological fusion line. No oral stoma or lips were
observed. The mandible and maxilla were severely hypo-
plastic. The hands and feet had complete syndactyly,
absent thumbs, and variable degrees of phalangeal hypo-
plasia. The affected individual had abnormal external geni-
talia and the anal orifice was stenotic. Antenatal history
was normal except for weak fetal movement. Sequencing
of RIPK4 in the genomic DNA of the affected individual
showed a homozygous one base-pair insertion in exon 5
(c.777_778insA), which was heterozygous in the parents012
(Figures 3D and 4A). This insertion is predicted to cause
a frameshift at arginine 260 and an altered sequence of
13 amino acids followed by a premature stop codon
(p.Arg260ThrfsX14) (Figure 4B). RNA from the affected
individual was not available for further investigation to
determine whether this premature stop codon triggers
nonsense-mediated decay of the mutant RNA or not.
The truncated protein is predicted to lose the last eight
amino acids from the carboxyl terminus of the kinase
domain, intermediate domain, and all ankyrin repeats of
the protein; therefore, it is expected to be nonfunctional.
RIPK4 is a member of the receptor-interacting protein
(RIP) kinase family, which is comprised of critical regula-
tors of the signal transduction mechanisms that mediate
cell survival and death.19,20 RIPK4 was initially reported
to interact with an isoform of the protein kinase C (PKC)
family and was referred to as PKC-delta-interacting protein
kinase (DIK) [MIM 605706].21 Independently, the mouse
ortholog of RIPK4 was described as a membrane-associated
protein kinase that interacts with PKCb on the basis of
yeast two-hybrid screening and was referred to as protein
kinase C-associated kinase (PKK).22 Afterward, because of
the similarities between the kinase domain of DIK and
PKK and that of the other RIP family members, DIK and
PKK were subsequently referred to as RIPK4 in humans
and mice, respectively.23
RIPK4 encodes a 784-amino acid protein (RIPK4) that
comprises an N-terminal serine/threonine kinase domain
followed by an intermediate region, and a C-terminal puta-
tive regulatory domain containing 11 ankyrin repeats.21–23
In the present study, the regions in which the RIPK4muta-
tions occurred—exons 2, 3, and 5—correspond to the
kinase domain of RIPK4 (Figures 4A–B). In order to analyze
the possible effects of the two amino acid substitutions
(p.Ile121Asn and p.Thr184Ile), a homology model of the
RIPK4 N-terminal kinase domain was built with YASARA
molecular modeling software (Figure 4D).24 Models were
built for the closest ten templates with the YASARA’s stan-
dard protocol hm_build.25 The best model was obtained
from the RCSB Protein Data Bank (PDB) 3PJC file (crystal
structure of JAK3 at 2.2 A˚ resolution),26 which yielded an
overall structure validation Z score of0.86. The placement
of ATP in the RIPK4model was derived from template 3PLS
(RON kinase), which contains an ATP analog.27 The
homology model is available from the authors upon
request. In this model, residue Ile121 is placed in helix 3
(Pro114-His133); it forms part of the hydrophobic core
and is in contact with the beta hairpin that supports the
magnesium-binding residues Asn148 and Asp161 in the
ATP-binding site. A mutation to asparagine thus has
obvious destabilizing effects, and the FoldX program28
predicts a reduction in protein stability of 11 kJ/mol.
The threonine residue (Thr184) is located even closer to
the active site in the A (Activation)-loop, which has been
reported to regulate access to the ATP-binding site and to
carry residues involved in autophosphorylation.28 As the
A-loop is rather flexible and exhibits large variabilityThe Ambetween homologs; its predicted structure is not entirely
reliable. Nevertheless and interestingly, Thr184 is found
to form a hydrogen bond with Asp 143—the key active
site residue that is assumed to abstract the proton from
the hydroxyl group to be phosphorylated.28 A mutation
to isoleucine disrupts this stabilizing interaction, and
FoldX predicts a smaller energetic cost of 3.3 kJ/mol, which
does not include the negative influence on the catalytic
activity of Asp 143. However, replacement of Thr184
with an alanine or glutamate via site-directed mutagenesis
disrupts the in vitro and in vivo kinase activity of the
RIPK4 protein.29 Substitution of aspartic acid with an
alanine or asparagine at position 143 also disrupts the
in vitro and in vivo kinase activity of the RIPK4.29,30 As
such, amino acid substitutions in both the Ile121 and
Thr184 positions have critical effects on the protein’s
stability and kinase activity, and thereby support their
causative nature of these mutations.
A luciferase reporter assay was also performed in order to
determine whether Ile121Asn, and Thr184Ile variants of
RIPK4 have enough activity to evoke a potent nuclear
factor-kB (NF-kB) response or not. To generate both
RIPK4 expression vectors (which harbor Ile121Asn and
Thr184Ile variants) previously described full-length
N-terminal Flag-tagged RIPK4 cDNA22 was used. The two
RIPK4 variants were recreated by site-directed mutagenesis
as an N-terminal Flag-tagged RIPK4 cDNA in a pCMV-
driven mammalian expression vector. The PCR products
were digested with Dpn I restriction enzyme (Agilent)
and transformed into One Shot TOP10 chemically com-
petent E. coli cells (Invitrogen). Clones harboring the
desired single nucleotide change were verified by DNA se-
quencing. Ile121Asn and Thr184Ile encoding vectors were
introduced transiently into HEK293T cells, along with
a NF-kB firefly luciferase reporter construct and a Renilla
luciferase reporter construct. Comparisons were made
with respect to wild-type RIPK4, the previously described
The184Ala mutant,29 and Chk2 constructs because CHK2
is a kinase that does not activate NF-kB, and hence it was
used as a negative control. The assays were performed
with a dual luciferase reporter assay system (Promega).
Whole-cell lysates were also subjected to SDS/8%PAGE
for immunoblotting analysis with anti-Flag to confirm
the expression levels of each of these proteins.
Luciferase reporter assays showed that both of the RIPK4
variants associated with the autosomal-recessive form of
popliteal pterygium syndrome, Ile121Asn and Thr184Ile,
were catalytically inactive in this study and failed to evoke
a robust NF-kB response (Figures 5 A–C). These data provide
further evidence that both Ile121 and Thr184 residues
located in the kinase domain of the protein are critical for
catalytic activity of RIPK4, and their substitution explains
the etiopatogenesis of the disease evaluated in this study.
Ripk4 is expressed in most tissues of the developing
mouse embryo—the highest level of expression occurs in
the basal and suprabasal layers of the epidermis—and plays
a role in the homeostasis of epidermal keratinocyteerican Journal of Human Genetics 90, 76–85, January 13, 2012 79
Table 1. Clinical Findings in Patients with the Autosomal-Recessive Form of Popliteal Pterygium Syndrome
Patient VI-3 (BPS1) V-12 (BPS1) IV-1 (BPS2) IV-1 (BPS3)
Consanguinity þ þ þ þ
Sex female female male female
Life span 18 months old (alive) 13 years old (alive) 57 days (deceased) 3.5 months (deceased)
Birth weight (at term) 2350 g 3.050 g 2200 g NA
Height at birth (due to pterygium) NA 37.4 cm 35 cm NA
Alopecia þ þ þ þ
Ectropion/lagophthalmos/keratitis þ//þ þ//þ þ/þ/þ //NA
Corneal ulcerations þ þ þ þ
Colobomas of lower eyelids þ  NA þ
Ankyloblepharon/blepharophimosis þ/þ þ/þ / þ/þ
Absence of eyebrows/eyelashes þ/þ þ/þ þ/þ þ/þ
Hypoplastic alae nasi and nose þ þ þ þ
Mouth border irregular irregular irregular absent
Hypoplastic oral/nasopharyngeal cavities þ/þ þ/þ NA NA
Orolabial synechia (filiform bands between jaws) þ þ þ no mouth opening
Cleft lip/palate þ (unilateral)/þ / þ (bilateral)/þ no lip/no palate
Low set ears þ þ þ 
Expressionless face þ þ þ þ
Upward slanting of palpebral fissures þ þ þ þ
Short neck þ þ  þ
Micrognathia þ þ NA þ
Limb Findings
Short, bowed limbs þ þ þ þ
Digital hypoplasia/thumb aplasia þ/þ þ/þ þ/þ þ/þ
Syndactyly of fingers/toes þ/þ þ/þ þ/þ þ/þ
Hypoplasia of nails þ þ þ þ
Absence of palmar/plantar lines þ þ þ NA
Arthrogryposis þ þ NA NA
Clubfoot deformity þ þ þ NA
Flexion contractures NA þ þ þ
Coetaneous and Musculoskeletal Findings
Popliteal/axillary/inguinal pterygia þ//þ þ//þ þ/þ/þ þ/þ/þ
Filiform bands between feet/feet and pelvic region þ/þ þ/ /þ NA
Anal stenosis/atresia/rectal polyps or skin tags // þ//þ // þ//þ
Genitourinary System
Bicornuate-bicollis uterus þ NA male NA
Hypoplastic labia major þ þ male þ
Micropenis/hypoplastic scrotum\ female female þ/þ female
Low set umbilicus þ þ þ þ
Inguinal hernia   þ NA
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Table 1. Continued
Patient VI-3 (BPS1) V-12 (BPS1) IV-1 (BPS2) IV-1 (BPS3)
Radiological Findings
Radius aplasia NA NA þ (unilateral left) /
Bowing of ulnae NA NA þ /
Hypoplasia of metacarpals/phalanges þ/þ þ/þ þ/þ þ/þ
Hypoplasia of iliac wing/pelvic bones/scapula /þ/NA þ/þ//þ þ/NA/NA NA
Cranial MRI normal normal NA NA
Abdominal and Renal USG normal normal ectopic kidney NA
Others
Dry, scaly skin þ//þ  þ þ
Asymmetric/wide-set nipples þ þ/þ /þ þ
Cardiac murmur patent foramen ovale   NA
Echocardiogram mitral regurgitation normal NA NA
Pulmonary hypoplasia    NA
Mental retardation NA  NA NA
Molecular Basis
RIPK4 mutation c.362T>A
(p.Ile121Asn)
c.362T>A
(p.Ile121Asn)
c.551C>T
(p.Thr184Ile)
c.777_778insA
(p.Arg260ThrfsX14)
NA is an abbreviation for not available or unknown.proliferation and differentiation.22,31,32 In Ripk4-deficient
mice, increased epidermal thickness due to abnormal kera-
tinocyte differentiation was reported even though the ker-
atinocyte proliferation rate was normal.15 The phenotypeThe Amof Ripk4/ mice is consistent with the human phenotype
observed in the presented affected individuals, both
phenotypes exhibit organ anomalies of surface ectoderm
origin, such as dry and scaly skin, corneal ulcerations,Figure 3. Mutation Analysis of RIPK4 in the
BPS2 and BPS3 Families
(A) Pedigree of family BPS2 shows consanguinity
and allele segregation. C and T below family
members III-1 and III-2 indicate the wild-type
and mutant alleles, respectively.
(B) Sequence chromatogram shows the identified
c.551C>T mutation in RIPK4 observed in family
BPS2. The upper chromatogram shows the
heterozygous mutant sequences from the parents
of affected individual IV-1, and the lower chro-
matogram shows the homozygous wild-type
sequences from a healthy control.
(C) The pedigree of family BPS3 shows consan-
guinity and allele segregation. The mutant allele
is shown below family members III-1, III-2, and
IV-4.
(D) Sequence chromatogram shows a one base-
pair insertion mutation (c.777_778insA) in
RIPK4 in family BPS3. The upper chromatogram
shows the homozygous mutant sequence in indi-
vidual IV-1, and the lower chromatogram shows
the homozygous wild-type sequences from a
healthy control.
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Figure 4. Diagrammatic Representation
of RIPK4 and In-Silico Analysis of the
RIPK4 Serine/Threonine Kinase Domain
(A) Diagram of RIPK4 and localization of
the identified mutations (c.362T>A,
c.551C>T, and c.777_778insA) through
the exons. The length of each exon is indi-
cated below the diagram.
(B) Diagram of the known functional do-
mains of human RIPK4 and localization
of the three identified mutations in the
serine/threonine kinase domain. Thenum-
bers of the first and last amino acids of the
each domain are shown below the diagram.
(C) Multiple alignments of all the partial
amino acid sequences of the known
RIPK4 serine/threonine kinase domain in
a variety of species. Amino acid positions
are indicated on the right side of the
alignments, and the missense mutations
(p.Ile121Asn and p.Thr445Ile) are shown
above the alignment.
(D) Molecular model of the RIPK4 kinase
domain showing the active site. Residues
Asn148 and Asp161 are predicted to
bind to ATP via an Mg2þ ion. The catalytic
residue Asp143 is stabilized by a hydrogen
bond to Thr184 (which is lost upon muta-
tion to isoleucine), whereas the second
residue of interest (Ile121) is located in
the background, forming part of the
hydrophobic core. Molecular graphics
were created with YASARA and POVRay
software. The following abbreviations are
used: N, Amino terminus of the kinase
domain; C, carboxyl terminus of the
kinase domain; A-loop: activation loop.hypoplastic alae nasi and nose, hypoplastic oral and naso-
pharyngeal cavities, orolabial synechia (filiform bands
between the jaws), cleft lip and/or palate, and hypoplastic
labia major. In addition, elevated expression of Ripk4
was noted in hair follicle keratinocytes, whereas its defi-
ciency leads to abnormal hair follicle development and
hair loss,15,16,31 as in the presented individuals that had
alopecia. Limb and digital malformations in both humans
and mice might also be a consequence of abnormal
development of the apical ectodermal ridge during
embryogenesis.
The physiological function of RIPK4 and the role of its
kinase activity are largely unknown; however, it has been
reported that RIPK4 is critical for activationofNF-kB,which
is involved in regulating keratinocyte differentiation. The
kinase domain of RIPK4 alone appeared to be as efficient
as full-length RIPK4 at activating NF-kB.16,19,30 NF-kB is
a dimeric transcription factor generated fromcombinations
of five structurally related proteins—NF-kB1 (p50), NF-kB2
(p52), RelA (p65), c-Rel, and RelB.33 NF-kB/Rel protein
complexes are retained in the cytoplasm of resting cells
because their nuclear localization signal is masked by IkB
inhibitoryproteins.34 In response to stimulation, IkBkinase
(IKK), which consists of two catalytic subunits (IKKa also
known as conserved helix-loop-helix ubiquitous kinase82 The American Journal of Human Genetics 90, 76–85, January 13, 2[CHUK] and IKKb) and one regulatory subunit (IKKg
[NEMO]), phosphorylates the IkBproteins. After phosphor-
ylation, IkB proteins undergo polyubiquitination and
subsequent degradation. When the IkB function is abol-
ished, NF-kB dimers translocate to the nucleus and activate
the expression of target genes.35,36 Several studies have
reported that the ubiquitously expressed NF-kB is a key
player in regulation of epidermal differentiation, apical
ectodermal ridge formation, limboutgrowth, digit develop-
ment, cellular proliferation, organdevelopment, apoptosis,
and immunity.37–40 Mice lacking Chuk (Chuk/ mice)
exhibit developmental abnormalities such as short limbs
and tails, rounded heads because of the shorter jaws and
nasal bones, syndactyly in both the fore and hind paws,
retarded hair follicle development, reduced skinfolds, and
predominant parakeratosis in the epidermis instead of an
enucleated cornified layer because of the defect of differen-
tiation of epidermal keratinocytes, and they die within
a few hours after birth.41–45 There are close similarities in
the phenotypes of Chuk knockout mice and Ripk4/
mice. CHUK is responsible for the noncanonical pathway
of NF-kB activation,46 whereas RIPK4 requires IKKb for the
induction of the canonical NF-kB pathway.30 However,
both canonical and noncanonical NF-kB signaling appear
to be required for epidermal differentiation in mice.012
Figure 5. Functional Analysis RIPK4 Variants Described in This
Study
RIPK4 and various mutants described in the text were cotrans-
fected with pBIIxLuc NF-kB firefly luciferase reporter and pRL-TK
Renilla luciferase reporter into HEK293T cells. Two representative
clones (denoted as Ile121Asn-1 and Ile121Asn-2, and Thr184Ile-1
and Thr184Ile-2) each harboring the desired disease-associated
RIPK4 variation were analyzed by this method.
(A) This figure depicts a typical luciferase assay, which was per-
formed in triplicate. The Renilla luciferase construct was used to
normalize for transfection efficiency. Data shown are mean 5
standard error of the mean.
(B) An aliquot from each of the cell lysates used above was loaded
on to SDS/8%PAGE gel and subjected to an anti-Flag immunoblot
and anti-b-actin immunoblot to determine protein expression.
(C) The remaining cell lysates were immunoprecipitated (IP) with
anti-Flag to enrich for Flag-tagged proteins, and then subjected to
immunoblotting analysis with anti-Flag to confirm the expression
levels of each of these proteins.Lahtela et al.47 reported two human fetuses with a lethal
condition known as Cocoon syndrome (MIM 613630),
which is characterized by severe abnormalities in brain
and facial structure and apparently absent limbs that are
bound to the trunk and encased under the skin; this
syndrome is a result of a homozygous stop codonmutation
in CHUK—the human ortholog of mouse Chuk. Fetuses
with Cocoon syndrome exhibit a more severe form of
Bartsocas-Papas syndrome. The present study’s results
clearly show that these syndromes are not allelic; however,
the morphological defects and skin abnormalities seen in
both syndromes are similar and consistent with pheno-
types observed in mice lacking genes that encode Chuk
and Ripk4, which suggests that these two genes mightThe Amfunction in closely linked pathways to regulate epidermal
development and differentiation. Transgenic experiments
have shown that Ripk4 functions in the epidermis via
PKC-dependent signaling pathways but Ripk4 cannot
rescue the defect seen mice that lack Chuk.16
NF-kB signaling pathway is also critical for proper IRF6
function in keratinocyte development.48,49 Transcription
of IRF6 is activated by DNp63a, which is the major isoform
of p63 encoded by TP63 (MIM 603273).50,51 Mutations of
TP63, disrupting the function of the isoform DNp63a,
causes developmental disorders that are characterized
by various degrees of limb abnormalities, ectodermal
dysplasia, and facial clefts.52 Various isoforms of p63
such as TAp63a and DNp63a function as direct upstream
elements of Chuk.53 DNp63 also interacts with structural
components cRel or RelA of the NF-kB/Rel protein complex
to form novel binding complexes on p63 or NF-kB/Rel
sites of multitarget gene promoters.54,55 Taken together,
these data suggest that IRF6, CHUK, and RIPK4 are impor-
tant components of closely related pathways to control
epidermal development.
The present study’s findings show that recessive muta-
tions in RIPK4 cause Bartsocas-Papas syndrome and its
variant, the autosomal-recessive form of multiple ptery-
gium syndrome (Aslan type). All mutations corresponded
to the serine/threonine kinase domain of the protein, indi-
cating the functional relevance of this domain. Missense
and nonsense mutations cause both the lethal and nonle-
thal recessive forms of multiple pterygium syndrome char-
acterized by severe organ anomalies of ectoderm origin.
The abnormalities observed in presented individuals were
similar but less severe than those seen in CHUK-deficient
human fetuses with Cocoon syndrome. The present
study’s findings point out that RIPK4 and CHUK might
function in closely related pathways to promote keratino-
cyte differentiation and epithelial growth.Supplemental Data
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